G protein-coupled receptors signal through a variety of mechanisms that impact cardiac function, including contractility and hypertrophy. G protein-dependent and G protein-independent pathways each have the capacity to initiate numerous intracellular signaling cascades to mediate these effects. G protein-dependent signaling has been studied for decades and great strides continue to be made in defining the intricate pathways and effectors regulated by G proteins and their impact on cardiac function. G protein-independent signaling is a relatively newer concept that is being explored more frequently in the cardiovascular system. Recent studies have begun to reveal how cardiac function may be regulated via G protein-independent signaling, especially with respect to the ever-expanding cohort of ␤-arrestin-mediated processes. This review primarily focuses on the impact of both G protein-dependent and ␤-arrestindependent signaling pathways on cardiac function, highlighting the most recent data that illustrate the comprehensive nature of these mechanisms of G protein-coupled receptor signaling. (Circ Res. 2011;109:217-230.)
G protein-coupled receptors (GPCRs) mediate numerous acute regulatory mechanisms involved in the control of cardiovascular function, such as contractility, and chronic processes, such as hypertrophy, that contribute to the development of cardiovascular diseases, including heart failure. 1, 2 Several current drug therapies, such as ␤-adrenergic receptor (␤AR) blockers and angiotensin II (Ang II) receptor (AT 1 R) blockers, target their GPCRs to prevent hypertrophic signaling and improve clinical outcomes of heart failure patients. 3 Recent research has shown that some GPCR ligands have the capacity to block hypertrophic signaling pathways while simultaneously promoting cardiac contractility or survival, 4 -7 a property that could improve overall cardiac function relative to conventional GPCR blockers. The ability of a ligand to relay such an effect is possible because of the variety of G protein-dependent and G protein-independent pathways that can be initiated on GPCR stimulation. G protein-dependent signaling pathways have been explored in the heart for decades, revealing significant roles for the G␣ s , G␣ i/o , G␣ q/11 , G␣ 12/13 , and G␤␥ families in mediating contractile or hypertrophic responses in the heart. Newer to the field of cardiac research, G protein-independent signaling has been studied for only the past 15 years, with specific roles for ␤-arrestinmediated signaling in the regulation of cardiac contractility and hypertrophy reported only in the past 5 years. The multitude of cardiac signaling pathways regulated by G proteins and ␤-arrestins downstream of GPCR activation provide a number of potential targets for pharmacotherapy of heart failure. This review highlights recent molecular studies that provide novel insight into the regulation of cardiac function via Gprotein-dependent and ␤-arrestindependent signaling.
G Protein-Dependent Signaling
The heterotrimeric G protein complex comprises a G␣ subunit, of which there are 4 main families (G␣ s , G␣ i/o , G␣ q/11 , and G␣ 12/13 ), coupled to a combination of G␤ and G␥ subunits, of which there exist 5 and 12 members, respectively. The specific classifications, isoforms, and various subunit compositions of the numerous G proteins have been described elsewhere. 8, 9 The G␣ proteins primarily expressed and studied in the heart include G␣ s , G␣ i1/2/3 , G␣ q/11 , and G␣ 12/13 (Table) . GPCR stimulation leads to a change in conformational of the receptor such that it promotes nucleotide exchange at G␣ of guanosine diphosphate (GDP) for guanosine triphosphate (GTP). 9 -11 The active GTP-bound form of G␣ dissociates from the receptor and G␤␥ subunits and subsequently activates/inhibits downstream effector proteins, 9 although G␣ subtype-selective molecular rearrangement with G␤␥ subunits in the absence of dissociation has also been reported. 12, 13 In recent years, an expansive array of accessory proteins that modulate G protein activity has been described, including activators of G protein signaling and regulators of G protein-signaling (RGS) proteins. 14, 15 Members of these families may contain GTPase-activating protein, guanine nucleotide exchange factor (GEF), or guanine nucleotide dissociation inhibitor activities, each of which contributes to the regulation of G protein activity. For instance, GEFs act to increase the rate of GTP association with G␣ subunits, thereby promoting G␣ protein-mediated effects, whereas guanine nucleotide dissociation inhibitor-containing proteins act to inhibit the dissociation of GDP from G␣ subunits, thereby inhibiting G␣-protein-mediated signaling. 14 RGS proteins containing GTPase-activating protein activity accelerate the GTPase activity of G␣ subunits, thereby decreasing the amplitude and duration of G␣-protein-mediated signaling, although these effects appear to be limited to mainly G␣ q/11 and G␣ i proteins. 15 The impact of G protein-dependent signaling via various GPCRs and downstream effector proteins on the regulation of cardiac function are discussed with regard to the molecular mechanisms by which they impact cardiac contractility and hypertrophy.
G Protein-Dependent Effects on Cardiac Contractility

cAMP-Mediated Regulation of Cardiac Contractility
The mechanisms by which G␣ s protein activity enhance heart rate and contractility are best exemplified by ␤ 1 AR signaling ( Figure 1 ). ␤ 1 AR stimulation results in adenylyl cyclase (AC)-mediated generation of cAMP and subsequent activation of protein kinase A (PKA). Via phosphorylation of numerous substrates involved in the contractile response, including the ryanodine receptor, phospholamban (PLB), the L-type calcium channel (LTCC), cardiac troponin I (cTnI), and cardiac myosin-binding protein C, PKA signaling enhances contractile function, as eloquently reviewed elsewhere. 16 Briefly, PKA-mediated phosphorylation of ryanodine receptor and LTCC (to increase Ca 2ϩ uptake and sarcoplasmic reticulum (SR) release), PLB (to release its inhibitory effects on the SR calcium ATPase and promote Ca 2ϩ SR storage), and TnI and cardiac myosin-binding protein C (to decrease Ca 2ϩ affinity for the myofilaments and alter cross-bridge kinetics) each contribute to the inotropic and lusitopic effects of ␤-adrenergic stimulation. Whereas 18 cAMP generation also leads to activation of exchange protein activated by cAMP (EPAC), and although the effects of EPAC signaling on contractile function have not been as extensively studied as PKA-mediated effects, EPAC also has been demonstrated to regulate cardiomyocyte Ca 2ϩ handling and myofilament protein phosphorylation. 19 Through mechanisms involving phospholipase C (PLC), protein kinase C (PKC), and calmodulin-dependent protein kinase II (CAMKII), EPAC has been shown to increase cTnI, ryanodine receptor, and PLB phosphorylation, Ca 2ϩ release from SR stores and sarcomeric shortening in response to either ␤AR stimulation or direct EPAC activation. 20 -23 Additionally, an interaction between CAMKII, EPAC1, and the scaffolding proteins ␤-arrestin 1 and ␤-arrestin 2 that was enhanced upon ␤1AR stimulation was demonstrated in the heart (Figure 1 ). 24 By providing a scaffold for both CAMKII and EPAC1, ␤-arrestins facilitate ␤1AR-EPAC-Rap1-PLC-PKC-mediated CAMKII activation and downstream PLB phosphorylation. 24 Cardiac electrophysiological processes 25, 26 also have been shown to be regulated by cAMP-dependent processes, because both PKA and EPAC have been shown to regulate ion channel activity. Whereas PKA-mediated phosphorylation of the ATP-sensitive K ϩ channel increases its activity leading to hyperpolarization, 27 EPAC activation leads to a Ca 2ϩ -calcineurin-dependent dephosphorylation/inactivation of vascular ATP-sensitive K ϩ channel, potentially providing a negative feedback mechanism to inactivate the channel when cAMP levels become very high. 28 Determination of EPACmediated effects on cardiac K ϩ channel activity and the comparative effects of EPAC vs PKA signaling on the contractile machinery and ion flux specifically in cardiomyocytes require further exploration.
Non-standard Abbreviations and Acronyms
In opposition to G␣ s -mediated signaling, stimulation of cardiac G␣ i protein-coupled receptors typically results in negative inotropy and chronotropy via G␣ i -dependent inhibition of AC activity, cAMP synthesis, and PKA activation. Of the G␣ i -linked GPCRs, the muscarinic acetylcholine receptor 2 is the primary example of G␣ i -mediated parasympathetic antagonism of sympathetic ␤AR signaling, and it has been shown to dampen, or block entirely, ␤AR-mediated inotropic and chronotropic responses (Figure 1 ). 29 The ability of G␣ i protein-coupled receptors to mediate inhibition of AC activity may depend on membrane localization because the ability of sphingosine-1-phosphate receptor-1 to decrease AC activity and inotropy in adult mouse ventricular myocytes was dependent on compartmentation of sphingosine-1-phosphate receptor-1 in caveolae-rich regions of the sarcolemma. 30, 31 
A Kinase-Anchoring Protein-Mediated Regulation of Cardiac Contractility
Via interactions with A kinase-anchoring proteins (AKAPs), PKA activity can be tethered to different substrates in subcellular environments, providing precise spatiotemporal regulation of cardiac function. 32 Studies over that past decade have shown that intracellular targeting of other components of cAMP-mediated signaling immediately downstream of ␤ARs, including AC and cAMP phosphodiesterases by AKAPs, tightly controls ␤AR signaling, 33 as is discussed in another review in this series. Aside from ␤AR-AKAP complexes, other GPCR-AKAP signaling complexes are beginning to be reported. The relaxin receptor was recently shown to be precisely regulated by constitutive association with AKAP79 -AC2 and ␤-arrestin 2-PKA-PDE4D3 complexes, which coordinately control local generation and hydrolysis of cAMP in response to low concentrations of relaxin. 34 Whereas relaxin has been shown to exert positive inotropic and chronotropic responses in the heart, 35 it is not known whether such an intricate scaffolding system mediates these responses in vivo.
Beyond regulation of local pools of cAMP at the receptor level, AKAPs also have been shown to regulate contractility at the level of the sarcomere as cardiac troponin T has been reported to act as an AKAP, targeting PKA activity to the sarcomere. 36 In addition, it has been shown that AKAP-9 recruits a macromolecular complex to the cardiac I Ks channel consisting of PDE4D3, PKA, and protein phosphatase-1, which tightly controls cAMP-induced channel activity and current, thereby modulating cardiac hyperpolarization. 37 In agreement with the variety of AKAP-mediated effects on cAMP signaling in cardiomyocytes, peptide-mediated disruption of PKA-AKAP interaction in the mouse heart has been shown to act as a negative inotropic, chronotropic, and lusitropic stimulus. 38
G␤␥-Mediated Regulation of Cardiac Contractility
Similar to the function of AKAPs, G␤␥ subunits can serve as a protein scaffold. 8 It has been shown that ␤ 2 AR-G␣ i protein coupling leads to G␤␥-mediated confinement of G␣ s -cAMP-PKA signaling via increased phosphoinositide-3-kinase activity. 39 In particular, G␣ i -phosphoinositide-3-kinase␥dependent regulation of phosphodiesterase-4 activity was shown to control local cAMP signaling in response to ␤ 2 AR stimulation and to dampen the ␤AR-mediated inotropic response in cardiomyocytes. 40, 41 Further, G␤ 1 interaction with nucleoside diphosphate kinase B was shown to regulate basal contractility in several cardiac cell models. [42] [43] [44] The nucleoside diphosphate kinase B-induced transfer of a phosphate to G␤ 1 allows the local generation of GTP bound to G␣ s and subsequent G␣ s activation, AC-mediated cAMP synthesis, and cardiomyocyte contractility. 42, 43, 45 Interestingly this process only impacts receptor-independent cAMP synthesis and cardiomyocyte contractility, 42 because activated GPCRs, such as ␤ARs, act as GEFs themselves to induce G␣ s protein exchange of GDP for GTP. 11 G␤␥ subunits can also promote negative inotropy via effects on ion channels, because G␤y-mediated inhibition of LTCC current after ␤AR stimulation has been reported. 46 Also, via a G␤␥-dependent mechanism, both muscarinic acetylcholine receptor 2 and sphingosine-1-phosphate receptor-1 have been demonstrated in atrial and ventricular myocytes to increase the open probability of the K ϩ channel IK Ach , promoting membrane hyperpolarization to decrease the action potential duration, thereby decreasing chronotropy and inotropy ( Figure 1 ). 31, 47 Via a G␥-like domain, RGS6 has been shown to interact specifically with G␤ 5 , 48 and a recent study reported that this complex binds to and promotes the deactivation of IK Ach , thereby modulating muscarinic acetylcholine receptor-2-mediated effects on myocyte current kinetics. 49 Because RGS proteins are involved in Figure 1 . Proposed G protein-dependent and ␤-arrestindependent mechanisms of contractility in ventricular myocytes. Stimulation of the G␣ s -coupled ␤ 1 AR leads to AC-mediated generation of cAMP and increased PKA activity, which can be regulated in subcellular domains by AKAPs and phosphodiesterases. PKA signaling enhances contractility via phosphorylation of cTnI, RyR, LTCC, and PLB. Modulation of the contractile machinery as well as Ca 2ϩ entry and release of SR-stared Ca 2ϩ , which binds to the myofilaments (actin, myosin, and troponin complex), act to induce contraction. A ␤-arrestindependent scaffold including EPAC and CAMKII can be recruited to ␤ 1 AR on stimulation, allowing cAMP-EPAC-mediated activation of CAMKII and regulation of contractility. Stimulation of the G␣ i -coupled muscarinic acetylcholine receptor 2 antagonizes AC activity and releases G␤␥ subunits that can open K ϩ channels to hyperpolarize the cardiomyocyte and dampen the contractile response, which is antagonized by RGS6. Stimulation of the G␣ q/11coupled AT 1 R leads to PLC␤-mediated generation of diacylglycerol, which subsequently leads to activation of PKC and PKD, and IP 3 , which induces the IP 3 receptor-mediated release of Ca 2ϩ from the SR that can activate CAMKII, all of which can regulate some or all of the same myofilament and ion channel targets as PKA. ␤-Arrestin scaffolds ARHGAP21 in response to AT 1 R stimulation, which leads to RhoA activation and effects on cytoskeletal structure, potentially influence cardiac contractility. (Illustration credit: Cosmocyte/Ben Smith).
promoting the reassembly of G␣ subunits and G␤␥ subunits into the heterotrimeric G protein complex, this study suggests that RGS6 provides a negative feedback mechanism to turn-off G␣ i -G␤␥-mediated hyperpolarization. Genetic ablation of RGS6 resulted in prolonged IK Ach activity in both atrial myocytes and sinoatrial node cells, leading to bradycardia. 49 
G␣ q/11 -Mediated Regulation of Cardiac Contractility
Cardiac G␣ q/11 -protein-coupled receptors increase cardiac inotropy by modulating intracellular Ca 2ϩ levels and contractile protein phosphorylation via PLC␤-mediated conversion of membrane inositol phospholipids into the second messenger products inositol trisphosphate and diacylglycerol. 50 Enhanced second messenger signaling downstream of G␣ q/11 increases SR-dependent Ca 2ϩ mobilization and activates a number of cardiac PKC isoforms, protein kinase D, and CAMKII. [51] [52] [53] Collectively, these kinases have been shown to modulate many of the same proteins involved in cardiomyocyte contractility as PKA ( Figure 1 ). 54 -61 Although acute stimulation of G␣ q/11 -protein-coupled receptors increases cardiomyocyte inotropy and chronotropy, 62-64 the physiological importance of such stimulation compared to ␤AR-G␣ smediated inotropy is not well-established. However, a number of important G␣ q/11 -activated signaling pathways can contribute to the regulation of contractility, which may be significant because cross-talk between cardiac G␣ q/11protein-coupled receptors and ␤AR-G␣ s signaling has been established. [65] [66] [67] [68] LTCC, PLB, and ryanodine receptor each contribute to Ca 2ϩ homeostasis and undergo phosphorylation by PKC and CAMKII signaling. 2, 59 For instance, phosphorylation of PLB can be increased in a PKC-dependent manner involving activation of CAMKII, 22 or it can be decreased in a PKC␣dependent manner involving protein phosphatase-1-mediated dephosphorylation. 56 Recently, the ␦ C isoform of CAMKII was shown in transgenic mice to mediate an alteration in myocyte Ca 2ϩ handling at the SR involving PLB, and that inhibition of its activity specifically at the SR helps to restore diastolic Ca 2ϩ handling. 69 Several putative PKC phosphorylation sites on LTCC have been reported, 70 which augments Ca 2ϩ influx in the cardiomyocyte to promote Ca 2ϩ -mediated Ca 2ϩ release from the SR. Different PKC isoforms can mediate LTCC phosphorylation, including PKC␣, but excluding PKC, although it has also been shown that PKC␣ can transiently decrease LTCC activity via a phosphoinositide-3-kinase␣-dependent mechanism after AT 1 R stimulation. 57 Beyond the control of ion flux, PKC and protein kinase D also have been reported to associate with or phosphorylate components of the cardiac contractile machinery, resulting in differential effects on Ca 2ϩ sensitivity and cross-bridge kinetics. 54, 60, 61 For instance, cTnI has been demonstrated to interact with PKC␣ after increased Ca 2ϩ signaling, which may result in the maintenance of contractile force. 58 In addition, cTnI has been shown to undergo phosphorylation by PKC␤II to increase Ca 2ϩ sensitivity, 55 and by PKC␣ and PKC to decrease Ca 2ϩ sensitivity in failing human myocardium. 54 In the latter study, PKC␣-dependent and PKCdependent phosphorylation of cardiac myosin-binding protein C, which is known to accelerate cross-bridge cycling, was also shown to be increased in failing human myocardium. Activated protein kinase D has been demonstrated to phosphorylate cTnI to actually decrease Ca 2ϩ sensitivity, 71 and may accelerate cross-bride cycle kinetics via phosphorylation of cardiac myosin-binding protein C. 72 Through these combined mechanisms, G␣ q/11 -mediated signaling has the capacity to regulate precise events involved in cardiac Ca 2ϩ transport and contractility.
G Protein-Dependent Effects on Cardiac Hypertrophy
G␣ q/11 Protein-Mediated Effects on Cardiac Hypertrophy
Whereas the physiological relevance of G␣ q/11 -protein signaling on cardiac contractility may not be as well-established as G␣ s -protein-mediated effects, G␣ q/11 signaling has been shown to play an important role in the development of cardiac hypertrophy. 51, 73, 74 Cardiac hypertrophy involves enhanced transcriptional activity and cell size, which can be a normal physiological adaptive response to increased cardiovascular workload or can contribute to the pathological development of heart failure. 75 Increased expression of various isoforms of sarcomeric and metabolic proteins considered to be representative of a developmental phenotype, or "fetal" gene expression, is associated with decreased cardiac function during the progression of hypertrophy and transition to heart failure (Figure 2 ). 76 The hypertrophic role of G␣ q/11 in the heart has been studied using genetic approaches to knockdown or inhibit G␣ q/11 in various mouse models of cardiomyopathy, demonstrating that hypertrophic responses to chronic agonist stimulation or pressure overload are reduced or prevented in the absence of G␣ q/11 activity, as reviewed by others. 75, 77 The regulation of G␣ q activity by RGS2, which normally dampens G␣ q signaling in the heart, also has been shown to influence cardiac hypertrophy. RGS2 knockout mice exhibit enhanced hypertrophic responses to pressure overload compared with RGS2-expressing mice, which include increased calcineurin expression, CAMKII activity, and mitogen-activated protein kinase (MAPK) activity, 78 suggesting that RGS2-mediated inhibition of G␣ q signaling could be an effective means by which to prevent cardiac hypertrophy. Similar results were shown in a recent study exploring the regulation of AT 1 R-induced MAPK signaling via RGS5 in neonatal cardiomyocytes. 79 Studies also have begun to comprehensively characterize the transcriptional response to G␣ q/11 signaling, revealing hundreds of genes whose expressions are altered after G␣ q/11 activation. These studies have reported an increase in G␣ q/11 -dependent transcript detection after stimulation with Ang II in HEK 293 cells or endothelin in rat neonatal cardiomyocytes. 66, 80, 81 In particular, investigators studying the effects of Ang II on transcription have shown that the Ang II-mediated increases in gene expression are primarily dependent on G␣ q/11 signaling. 66 By blocking G␣ q/11 -protein-dependent signaling, antagonists such as AT 1 R blockers can diminish the hypertrophic transcription response to stimulation by endogenous factors and reduce the rate of progression of heart failure. 3
PLC-PKC-MAPK-Mediated Effects on Cardiac Hypertrophy
Aside from the antagonism of G␣ q/11 -protein-coupled receptors or G␣ q/11 itself, inhibition of several downstream regulatory proteins has been shown to interfere with G␣ q/11mediated hypertrophic responses. As discussed, G␣ q/11 activation initiates PLC␤-mediated phospholipid hydrolysis and second messenger generation. A 32-amino acid C-terminal peptide of PLC␤1b was shown to be sufficient to prevent sarcolemmal targeting of PLC␤1b in rat neonatal cardiomyocytes. 82 By blocking PLC1␤1b targeting to the membrane, PLC-mediated second messenger generation and subsequent hypertrophic responses were abrogated in response to ␣ 1 AR stimulation. 82 Downstream of PLC, PKC activation leads to phosphorylation of numerous substrates and, in the context of hypertrophy, initiation of MAPK signaling is a major route by which G␣ q/11 -coupled receptors mediate cell growth responses. 83 In particular, activated PKCs are known to increase ERK1/2 activity in the heart to increase cell growth, effects that can be prevented with PKC inhibition. 51 Via both cytosolic and nuclear actions, ERK1/2 signaling has been shown in different cell types to increase DNA transcription and mRNA translation. 84, 85 Such subcellular effects of ERK1/2 also have been demonstrated in neonatal rat cardiomyocytes to contribute to cardiac growth responses, including modulation of proteins involved in gene expression and protein synthesis, such as the nuclear transcription factor family nuclear factor of activated T cells and the ribosomal S6 kinase p70S6K. 86, 87 Interestingly, it was recently demonstrated that ERK1/2 in particular contributes to concentric cardiomyocyte hypertrophy, or increased cardiomyocyte width, associated with the addition of new sarcomeres, likely mediated via cytosolic pools of activated ERK1/2. 88 Inhibition of ERK1/2 signaling, however, led to increased cardiomyocyte length or eccentric hypertrophy. Inhibition of downstream phosphorylation targets of ERK1/2, including mitogen and stress-activated kinase 1 and MAP kinase-interacting kinase 1, also has been shown to reduce the Stimulation of the AT 1 R leads to G␣ q/11 -mediated signaling that can be antagonized by RGS2 and ␤-arrestin recruitment. PLC␤ activity leads to diacylglycerol and IP 3 generation and downstream activation of PKC, ERK1/2, CAMKII, and calcineurin, each of which can increase the transcriptional response in the nucleus. AT 1 R-G␣ 12/13 -mediated signaling through p115RhoGEF leads to c-Jun NH(2)-terminal kinase activation that can also regulate transcription. ␤AR-G␣ s stimulation leads to AC-generated cAMP accumulation and increased PKA activity, which can also modulate gene transcription. EPAC activation, possibly downstream of ␤AR stimulation, also leads to CAMKII and calcineurin activation via Ca 2ϩ mobilization. Increased cardiomyocyte transcription in response to hypertrophic stimuli can lead to an increase in fetal gene expression. The ␤-arrestin-mediated ␤AR signaling also can regulate hypertrophy via an unknown mechanism. Also, ␤-arrestindependent ␤ 1 AR-mediated EGFR transactivation decreases cardiac apoptosis, possibly via internalization of a ␤ 1 AR-EGFR-ERK1/2 complex that directs an unknown cytosolic cell survival response. Internalization of an AT 1 R-␤-arrestin-ERK1/2 complex has been shown to increase MAP kinase-interacting kinase 1 activation to enhance eukaryotic translation initiation factor-4E-mediated mRNA translation, which could contribute to an increase in cell size and protein content, and thus hypertrophy and decreased cardiac function in response to hypertrophic stimuli. AT 1 R-␤-arrestin-ERK1/2-mediated activation of 90-kDa ribosomal S6 kinase has been shown to inhibit BAD-induced apoptosis, which could contribute to cardiomyocyte cell survival. (Illustration credit: Cosmocyte/Ben Smith).
hypertrophic response to G␣ q/11 -protein-coupled receptors, such as the ␣ 1 AR, in cardiomyocytes. 89, 90 
CAMKII-Mediated Effects on Cardiac Hypertrophy
In addition to PKC-MAPK signaling, activation of G␣ q/11 mediates hypertrophy via other mechanisms. PLC␤generated inositol trisphosphate binds to inositol trisphosphate receptors on the SR to increase the release of stored Ca 2ϩ into the cytosol, where it binds calmodulin (CAM). The resulting Ca 2ϩ /CAM complex interacts with and activates numerous proteins, including CAMKII and calcineurin (Figure 2) , a protein phosphatase that regulates nuclear factor of activated T cells and has been shown to play a role in this development of hypertrophy in various models. 83, 91 The role of CAMKII in hypertrophy and development of heart failure has been extensively studied by Brown et al 53 using various genetic mouse models. From these studies, the notion that select isoforms of CAMKII can play distinct, but overlapping, roles in the promotion of hypertrophic signaling in the heart has emerged. In particular, it was shown that despite differential localization of the ␦ B , and ␦ C cardiac isoforms of CAMKII in the nucleus and cytosol, respectively, transgenic expression of each isoform enhanced cardiac hypertrophic gene expression by promoting histone deacetylase-4 extrusion from the nucleus. 92 Interestingly, genetic deletion of CAMKII␦ in mice did not prevent the development of hypertrophy, ostensibly attributable to a compensatory increase in CAMKII␥ activity, but did attenuate heart failure progression after pressure overload attributable to a loss of altered expression of Ca 2ϩ regulatory proteins. 93 This reveals a CAMKII isoform-specific transcriptional control of subsets of cardiac proteins. Most recently, CAMKII␦ deletion has been demonstrated to improve cardiac function and reduce remodeling in various mouse models of heart failure, 53 including myocardial ischemia, ischemia/reperfusion, and transgenic overexpression of G␣ q . Thus, inhibition of CAMKII signaling appears to be a viable mechanism to attenuate hypertrophy and progression to heart failure, although isoform-specific targeting and compensatory effects may need further exploration.
G␣ 12/13 -Mediated Effects on Cardiac Hypertrophy
Contrary to G␣ q/11 signaling, G␣ 12/13 activation does not lead to the generation of second messengers, but rather to the activation of a small family of RhoGEFs. 94 RhoGEFs induce the activation of the small GTPase RhoA, which in turn mediates numerous cellular processes through effects on several downstream protein targets. 95 Although G␣ 12/13 signaling in the heart is still relatively unexplored, several studies from the Kurose laboratory have shown a role for G␣ 12/13 in mediating cardiac hypertrophy and fibrosis. AT 1 R, ␣ 1 AR, and ET-1 stimulation were each shown in neonatal cardiomyocytes or cardiac fibroblasts to be capable of inducing hypertrophic or fibrotic responses, mainly via G␣ 12/13 -p115RhoGEF-dependent activation of the MAPK c-Jun NH(2)-terminal kinase (Figure 2 ). 96 -99 Another group also has reported that AKAP-Lbc acts both as a scaffold to induce ␣ 1 AR-mediated p38 MAPK activation and as a RhoGEF to activate RhoA after ␣ 1 AR-G␣ 12/13 stimulation in neonatal cardiomyocytes. 100, 101 In addition, it was shown that either mechanical stretch or direct stimulation of the purinergic P2Y 6 receptor increases cardiomyocyte fibrosis via G␣ 12/13 and that P2Y 6 inhibition in vivo prevented fibrosis, but not hypertrophy, in response to pressure overload. 102 Thus, although G␣ 12/13 effects in the heart have not been as extensively studied as G␣ q/11 -mediated effects, they may be important mediators of cardiac hypertrophy and fibrosis.
cAMP-Dependent Effects on Cardiac Hypertrophy
Although a role for G␣ s in the development of hypertrophy has been recognized for many years, 103 as illustrated via transgenic overexpression of cardiac G␣ s , 104, 105 the mechanisms controlling hypertrophy downstream of G␣ s and cAMP generation remain controversial. At the level of G␣ s , a recent study highlighted the ability of RGS2 to influence the hypertrophic response to ␤AR stimulation, because RGS overexpression in neonatal rat ventricular myocytes diminished ␤AR-mediated cAMP synthesis, ERK1/2 and Akt phosphorylation, and hypertrophy. 106 Additionally, using selective activators of PKA and EPAC, the authors demonstrated reliance on PKA signaling for the induction of cardiomyocyte hypertrophy with no EPAC-mediated effects on cell growth. Conversely, another group demonstrated a role for EPAC in the hypertrophic responses to both pressure overload and ␤AR stimulation. In a rat model of aortic constriction, both EPAC1 expression and myocardial hypertrophy increased and it was shown in isolated adult rat ventricular myocytes that the effects of EPAC on cell growth involve Ras, calcineurin, and CAMKII signaling. 107 It was subsequently shown in neonatal rat cardiomyocytes that Ras activation in response to EPAC stimulation was dependent on PLC-mediated and inositol trisphosphate receptor-mediated increased Ca 2ϩ signaling, and that both calcineurindependent nuclear factor of activated T-cell transcription and CAMKII-dependent myocyte enhancer factor-2 activation contributed to the hypertrophic response. 108 Although the mechanisms by which EPAC regulates cardiac hypertrophy are still being explored, there is evidence to support a role for EPAC in this process ( Figure 2 ) and to suggest that EPAC could provide a novel therapeutic target.
G␣ i -Mediated and G␤␥-Mediated Effects on Hypertrophy
Both G␣ i and G␤␥ have been implicated in the development of hypertrophy and the progression of heart failure. An increase in cardiac G␣ i1 expression was detected in an inducible genetic model of Ras-MAPK-mediated hypertrophy, correlating with alterations in the regulation of intracellular Ca 2ϩ handling and leading to ventricular hypertrophy and arrhythmia, both of which were normalized with the inhibition of G␣ i via pertussis toxin. 109 Also, genetic inhibition of G␣ i with a cardiac-expressed inhibitory peptide was shown to increase apoptosis after ischemia/reperfusion injury, identifying a cardioprotective role for G␣ i during cardiac stress. 110 More recently, it was shown that small molecule inhibition of G␤␥ was able to halt the progression of heart failure in both a neurohormonal and a genetic mouse model of heart failure. 111 In each model, contractile function was improved with G␤␥ inhibition, and the hypertrophic response was reduced, as assessed by cardiomyocyte morphology and changes in fetal gene expression. Because small molecule inhibitors of G␤␥ have been shown to differentially modulate
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Cardiac G Protein and ␤-Arrestin Signaling different G␤␥-dependent signaling pathways, 8 the potential to selectively inhibit distinct cardiac G␤␥-mediated hypertrophic effects while preserving contractile function could be advantageous.
G Protein-Independent Signaling
GPCR-mediated G protein-independent signaling is a newer concept compared to G protein-dependent signaling. The diverse nature of this signaling paradigm has become apparent over the past decade, and great strides have been made in unraveling the roles of G protein-independent signaling in the cardiovascular system. GPCR stimulation and subsequent phosphorylation of C-terminal serine/threonine residues by GPCR kinases (GRKs) relay the primary steps in the induction of G protein-independent signaling by inducing the recruitment of ␤-arrestins. 112 Because the role of GRKs in cardiovascular signaling and function are reviewed elsewhere in this series, the following discussion of G protein-independent signaling focuses on recent developments in the understanding of the signaling networks used by ␤-arrestins. ␤-arrestins 1 and 2 are ubiquitous scaffolding proteins that induce receptor desensitization, internalization, and numerous signaling mechanisms. 113 Recently, identification of entire ␤-arrestin-interacting protein signalosomes via mass spectroscopy has greatly expanded the comprehension of the scope of ␤-arrestin signaling. In particular, the ␤-arrestin signalosomes that associate with AT 1 R before and after Ang II stimulation have been reported in HEK 293 cells, identifying hundreds of proteins that scaffold differentially with ␤-arrestins 1 and 2. 114 Additionally, the identification of hundreds of proteins whose phosphorylation status is altered after stimulation of AT 1 R also reveals entire AT 1 R-␤-arrestin-dependent phosphoproteomes involved in numerous processes, including cell growth, cell survival, and cytoskeletal reorganization. 115, 116 Although a majority of studies investigating ␤-arrestin-mediated effects have focused on the downstream responses to AT 1 R or ␤AR stimulation, the increasing array of results may be applicable to other cardiac GPCR systems as they relate to the control of cardiac contractility and hypertrophy.
␤-Arrestin-Mediated Effects on Cardiac Contractility
␤-Arrestin-Dependent Cardiomyocyte Contractility
In the past 5 years, ␤-arrestins have been demonstrated to promote cardiomyocyte and cardiac contractility. Studies using ␤-arrestinbiased AT 1 R ligands that do not induce G␣ q/11 protein activation have shown that AT 1 R-␤-arrestindependent signaling enhances contractility in isolated adult mouse cardiomyocytes. [5] [6] [7] The first study, which utilized the biased ligand [Sar 1 , Ile 4 , Ile 8 ]-angiotensin II and knockout mice to define the roles of each ␤-arrestin in increasing cardiomyocyte contractility, identified ␤-arrestin 2, but not ␤-arrestin 1, as the mediator of this G␣ q/11 -independent response. 5 The reliance on ␤-arrestin 2 in mediating G␣ q/11protein-independent contractility in response to AT 1 R stimulation was confirmed in a more recent study utilizing a distinct ␤-arrestinbiased AT 1 R ligand. 6 In addition, unbiased activation of AT 1 R with Ang II in ␤-arrestin 2 knockout cardiomyocytes produced a blunted contractile response, 6 suggesting that ␤-arrestin 2-mediated effects on contractility may not be redundant with respect to G␣ q/11 proteindependent signaling. Violin et al 7 have recently demonstrated in whole animals that infusion of synthetic ␤-arrestinbiased AT 1 R peptide ligands cause increased cardiac contractility. Interestingly, although these ␤-arrestinbiased AT 1 R ligands increased cardiac contractility and decreased blood pressure, they did not alter stroke volume, unlike conventional AT 1 R blockers. 7 The therapeutic implications for these ligands are discussed in another review in this series, but these observations demonstrate the potential of targeting ␤-arrestin-mediated signaling pathways to selectively impact cardiovascular function.
␤-Arrestin-Mediated Effects on Cytoskeletal Reorganization
The mechanisms responsible for mediating ␤-arrestindependent cardiomyocyte contractility have not yet been defined but could involve the aforementioned ability of ␤-arrestins to scaffold proteins involved in regulating contractility, such as EPAC and CAMKII. 24 Additionally, cytoskeletal reorganization could play a role in ␤-arrestin-mediated cardiac contractility. Mechanistic studies in HEK 293 cells have reported ␤-arrestin-mediated effects on cytoskeletal reorganization, mainly describing effects on the small GTPase RhoA downstream of AT 1 R. AT 1 R-␤-arrestin 1-mediated signaling has been shown to increase RhoA activation and subsequent stress fiber reorganization, whereas ␤-arrestin 2 was shown to have no impact on this process, 117 highlighting distinct functional roles for ␤-arrestins 1 and 2 in regulating this intracellular process. In addition, increased ␤-arrestin 1 association with a Rho GTPase-activating protein (ARHGAP21) after AT 1 R stimulation was recently demonstrated to promote RhoA activation and stress fiber formation (Figure 1) , whereas disruption of this interaction diminished RhoA activity and changes in actin reorganization and cell shape. 118 Perhaps explaining the lack of effect of ␤-arrestin 2 in mediating RhoA activation downstream of AT 1 R, it was shown that unlike ␤-arrestin 1, ␤-arrestin 2 does not interact with ARHGAP21. 118 Interestingly, another group reported a dependence on ␤-arrestin 2, but not ␤-arrestin 1, in the RhoA-RhoA kinase-dependent regulation of myosin light chain kinase activity and plasma membrane blebbing after AT 1 R stimulation. 119 How AT 1 R stimulation promotes one ␤-arrestin-mediated pathway over another to confer changes in cytoskeletal organization is not clear but could depend on local concentrations of the mediators of these effects. Although ␤-arrestin-mediated activation of RhoA signaling is an attractive explanation for increased cardiomyocyte contractility because RhoA activity can impact regulators of cardiac contractility such as PKC and protein kinase D, 95 the impact of RhoA signaling in ␤-arrestin-mediated contractility requires exploration. Additional proteins known to be involved in the regulation of contractility have been demonstrated to interact with ␤-arrestins or have their phosphorylation status altered in a ␤-arrestindependent manner downstream of AT 1 R stimulation. These include RhoA kinase, actin, cofilin, myosin, and the myosin-binding subunit of myosin phosphatase, 114 -116 and extend to other proteins involved in more generalized signaling processes. Further, ␤-arrestindependent regulation of Ca 2ϩ transport via transient receptor potential channel has been reported in vascular smooth muscle cells. 120 After Ang II stimulation, a ␤-arrestin 1-dependent AT 1 R-transient receptor potential-4 complex undergoes internalization away from the plasma membrane, reducing cation influx in response to continued AT 1 R stimulation. Altogether, the expanding roles for ␤-arrestins in the regulation of cation influx, cytoskeletal structure, and cardiomyocyte contractility suggest that they provide a previously unrecognized mechanism to regulate cardiac contractile function. Whether the mechanistic observations reported thus far extend from cell culture models to the heart and apply to cardiac GPCRs other than AT 1 R remains to be tested.
␤-Arrestin-Mediated Effects on Cardiac Hypertrophy
␤-Arrestin-Mediated MAPK Activity Some GPCRs, such as the AT 1 R, form stable complexes with ␤-arrestins after ligand stimulation and internalization, which promotes prolonged MAPK signaling compared to G protein-initiated signaling, as exemplified by ␤-arrestin-ERK1/2 signaling. 113 Often, G protein-dependent ERK1/2 signaling results in increased nuclear ERK1/2 activity; 85, 121 however, ␤-arrestin-mediated scaffolding of ERKs has been shown for several receptors to restrict ERK1/2 signaling to the cytosol. [122] [123] [124] [125] The function of this type of ERK1/2 signaling is still being explored, but the major effects of cytosolic ␤-arrestin-ERK1/2 signaling thus far have been shown to impact processes involved in cardiomyocyte survival and hypertrophy such as apoptosis and protein synthesis. 84, 125, 126 AT 1 R-␤-arrestin 2-dependent cytosolic ERK1/2 signaling allows phosphorylation and activation of 90-kDa ribosomal S6 kinase, shown in neonatal cardiomyocytes to increase DNA synthesis and proliferation. 125 In addition, MAP kinaseinteracting kinase 1 has been shown to interact with ␤-arrestin 2 and to become activated in an AT 1 R-␤-arrestin-ERK1/2-dependent manner in vascular smooth muscle cell, leading to phosphorylation of the cap binding complex member protein eukaryotic translation initiation factor-4E and increased protein synthesis, which could be a mechanism common to cardiomyocytes as well ( Figure 2 ). 84 Interestingly, ERK1/2 activity downstream of some GPCRs has been shown to be reciprocally regulated by ␤-arrestins 1 and 2. G protein-independent ERK2 activation downstream of the AT 1 R, for instance, has been demonstrated to be mediated by ␤-arrestin 2, whereas ␤-arrestin 1 impedes ␤-arrestin 2-mediated ERK2 scaffolding and subsequent activation. 127 Although an initial report has revealed opposing roles for ␤-arrestins 1 and 2 in the regulation of neointimal hyperplasia, 128 the consequence of such reciprocal regulation of ERK signaling in the heart has not been studied.
␤-Arrestin-Dependent EGFR Transactivation
An additional mechanism by which ␤-arrestins direct ERK1/2 signaling and may impact cardiomyocyte hypertrophy, as well as survival, is via transactivation of epidermal growth factor receptor (EGFR). Several GPCRs have been reported to induce EGFR transactivation and ERK1/2 activity, which may contribute to hypertrophy. 129 -131 Whereas the molecular pathways involved in this process vary for different GPCRs, a significant role for ␤-arrestins in ␤ARmediated EGFR transactivation has been demonstrated, because siRNA-mediated deletion of either ␤-arrestin or overexpression of mutant forms of ␤-arrestins prevents EGFR transactivation, ␤AR internalization, and ERK1/2 activation. [132] [133] [134] The importance of ␤ 1 AR-mediated EGFR transactivation has been demonstrated in a mouse model of heart failure in which chronic catecholamine stimulation induced dilated cardiomyopathy and increased cardiac apoptosis in mice unable to induce transactivation, compared to mice that were capable of inducing this pathway. 133 The mechanisms relaying survival in response to ␤ 1 AR-mediated EGFR transactivation have not been elucidated but may involve the interaction and cytosolic trafficking of a ␤1AR-EGFR-ERK1/2 complex in a ␤-arrestindependent manner ( Figure 2 ). 134 Similar to ␤ 1 AR, urotensin II-mediated EGFR transactivation was recently shown to be ␤-arrestindependent and to reduce cardiac apoptosis in a mouse model of pressure overload compared to mice in which EGFR was inhibited. 129 However, the role of ␤-arrestins in GPCRmediated EGFR transactivation and the effect of this signaling paradigm on cardiomyocyte growth and survival may be GPCR-specific. Sadoshima et al 131, 135 have shown that Gprotein-independent AT 1 R-mediated transactivation of EGFR after Ang II stimulation augments isolated cardiac fibroblast proliferation, as well as both cardiac hypertrophy and apoptosis in vivo, although these studies did not specifically explore ␤-arrestins in these processes. Conversely, a recent report from Smith et al 136 indicates that AT 1 Rmediated EGFR transactivation and subsequent hypertrophy is completely dependent on G␣ q/11 -protein-coupling in neonatal rat ventricular cardiomyocytes, whereas ␤-arrestins play no role in this process. Interestingly, ligand-independent AT 1 R-mediated EGFR transactivation in the heart in response to mechanical stretch was shown to relay prosurvival signaling, enhancing Akt activation and maintaining lower rates of apoptosis in a ␤-arrestin 2-dependent manner. 137 Therefore, EGFR transactivation can enhance both cardiac survival and hypertrophy, although the roles of ␤-arrestins vs G proteins in mediating these processes appear to be GPCR-specific and ligand-specific.
␤-Arrestin-Mediated Antiapoptotic Signaling
Aside from playing a role in EGFR transactivation-mediated antiapoptotic signaling, the ability of ␤-arrestins to negatively regulate apoptosis downstream of various GPCRs has been known for some time. 138 The mechanisms relaying this effect have not been completely elucidated, although ␤-arrestin interaction with proteins involved in the regulation of apoptosis have been identified. 114 Thus far, ␤-arrestin 2-mediated stabilization of inactive glycogen synthase kinase-3␤ has been shown to contribute to a decrease in apoptosis, 139 as have interactions of ␤-arrestins with other proteins. Heat shock protein 27 has been identified as a ␤-arrestin-interacting protein that confers cytoprotective signaling after ␤ 2 AR stimulation by decreasing caspase activity. 140 Also, apoptosis signal-regulating kinase 1 has been shown to associate with ␤-arrestins, which promote the ubiquitination and proteosomal degradation of apoptosis signal-regulating kinase 1, thereby decreasing rate of apoptosis. 141 ERK1/2 signaling has been shown to mediate many ␤-arrestindependent effects, including apoptosis. AT 1 R-␤-arrestin 2-ERK-mediated phosphorylation of 90-kDa ribosomal S6 kinase in vascular smooth muscle cells has been demonstrated to promote phosphorylation of BAD (Figure 2) , a regulatory protein involved in the promotion of cellular apoptosis. 126 The 90-kDa ribosomal S6 kinase-mediated phosphorylation of BAD increases its association with the scaffolding protein 14-3-3 and conversely decreases its association with the proapoptotic Bcl-xL, thereby diminishing vascular smooth muscle cell apoptosis. 126 This mechanism has since been confirmed by another group studying GLP-1 receptor-␤arrestin 1-mediated effects on apoptosis. 142 Identification of the mechanisms by which ␤-arrestins regulate apoptosis downstream of GPCRs specifically in the heart requires additional study, but that will help define the impact of ␤-arrestins on cardiac remodeling during the progression of a pathological state such as heart failure.
␤-Arrestin-Dependent Regulation of Gene Expression
Recent studies have begun to describe the effect of ␤-arrestin signaling on gene expression as well as on specific transcriptional regulators. Stimulation of various GPCRs can increase the association of ␤-arrestins with proteins, including the nuclear factor-B inhibitor protein IB␣ and the histone acetyltransferase p300, which can enhance or diminish transcriptional activity. [143] [144] [145] In addition, ␤-arrestins have been demonstrated to play a complex role in ET A R-mediated control of ␤-catenin phosphorylation and nuclear translocation, promoting a transcriptional response in ovarian cancer cells (also reviewed recently). 146 Although many studies exploring the impact of ␤-arrestin-mediated signaling on transcription have focused on cancer progression, immune responses, and central nervous system signaling, [145] [146] [147] the role of ␤-arrestins in regulating gene expression in response to cardiac-expressed GPCRs has begun to be characterized. ␤-arrestin 1 was demonstrated to be essential for the ␤ 1 ARmediated increase in protein content and fetal gene expression in neonatal rat cardiomyocytes in response to catecholamine stimulation. 148 Whereas ␤-arrestin-1 was demonstrated to be important in this process, the intermediate signaling components between ␤-arrestin 1 and increased gene expression were not completely elucidated, although a role was confirmed for Akt, 148 a protein kinase known to be involved in mediating cardiac hypertrophy. 51 The role of ␤-arrestin signaling in the induction of cell proliferation and gene expression has been explored most extensively in response to AT 1 R stimulation in cell culture models. AT 1 R-mediated EGFR transactivation was shown to increase vascular smooth muscle cell DNA synthesis in a ␤-arrestin 2-ERK-dependent manner, 130 although the regulation of gene expression was not directly measured. Whereas Ang II was shown in increase the expression of hundreds of genes in HEK 293 cells, AT 1 R-␤-arrestin-dependent signaling was found to increase the expression of very few genes, indicating that ␤-arrestins normally act to dampen the AT 1 R-G␣ q/11 -protein-induced hypertrophic response without directly contributing to a significant alteration in gene expression. 66, 81 Although ␤-arrestin signaling was shown to lack a robust impact on the regulation of genes directly downstream of AT 1 R, AT 1 R-␤-arrestin signaling was demonstrated to potentiate the gene regulation response induced by ␤ 2 AR stimulation. 66 Cross-talk between AT 1 R-induced and ␤ARinduced signaling on cardiomyocyte contractility and ERK activation has been established 65, 67 and thus could be an important feature of ␤-arrestin-mediated effects on hypertrophy. AT 1 R-␤-arrestin signaling also has been recently demonstrated to increase phosphorylation of transcriptional regulators commonly associated with distinct GPCR systems; 116 therefore, studying the coordinated effects of multiple stimulated GPCRs could provide a more comprehensive understanding of gene expression changes.
Conclusion
With the increasingly diverse array of G protein-dependent and G protein-independent signaling pathways identified that contribute to GPCR-mediated regulation of cardiac function, there exist several challenges in trying to interpret and translate them into therapeutic strategies. A significant challenge lies in extrapolating information from the diverse array of model systems used for exploring signaling mechanisms to a clinical setting, especially with regard to ␤-arrestin-mediated effects on cardiac function. Because G protein-dependent signaling has been investigated for decades, studies have been performed in several neonatal and adult cardiomyocyte cell systems and in whole heart in vivo, giving credence to the importance of these pathways in humans. Still, as more detailed information describing previously unappreciated roles for known effectors or novel regulators of G proteindependent signaling are reported, further validation of their contribution to the regulation of human cardiac function is needed. Although numerous signaling pathways have been shown to be activated in a ␤-arrestindependent manner, as demonstrated mainly in AT 1 R-focused and ␤AR-focused studies in noncardiomyocyte cell models, the use of these networks in the regulation of cardiac function under normal or pathological conditions and in response to other GPCRs remains to be fully explored. Another challenge relates to determining the significance of two or more signaling pathways mediating similar processes via modulation of either the same or different targets. For instance, although AT 1 R stimulation may regulate hypertrophy via G␣ q/11 -dependent, G␣ 12/13 -dependent, and ␤-arrestindependent pathways, is there redundancy in the activation of these pathways, or do they each serve a specific purpose during pathological development of heart failure? Also, the precise spatiotemporal targeting of signaling scaffolds by AKAPs, G␤␥ subunits, and ␤-arrestins introduces an extra level of consideration for how GPCR-mediated effects on cardiac function may be fine-tuned. Further complexity lies within the interaction of different receptor systems at a given time in physiological or pathological regulation of cardiac function. Because the simultaneous activation of numerous GPCRs has the potential to initiate myriad signaling pathways, how are these indepen-dent or overlapping events integrated to regulate cardiac contractility or hypertrophy? Although assembling a comprehensive interpretation of GPCR-mediated regulation of cardiac function is difficult, it is also exciting as points of interaction between G protein-dependent and G proteinindependent pathways continue to be discovered.
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